RECURRENT TRANSFORMED FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for RECURRENT TRANSFORMED FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT TRANSFORMED FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT TRANSFORMED FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo offers hope for Tough-to-Treat lymphoma
Disease control Recruiting nowThis study tests a two-step treatment for adults with large B-cell lymphoma that returned or didn't respond to prior therapy. First, patients receive tafasitamab (an antibody that targets cancer cells) plus lenalidomide (a drug that helps the immune system fight cancer). Then, th…
Matched conditions: RECURRENT TRANSFORMED FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated May 17, 2026 05:37 UTC
-
New combo therapy aims to boost remission in tough lymphoma cases
Disease control Recruiting nowThis study tests whether adding the drug epcoritamab to standard chemotherapy and a stem cell transplant can improve outcomes for people with large B-cell lymphoma that has returned or not responded to prior treatment. About 25 adults will receive the combination therapy. The goa…
Matched conditions: RECURRENT TRANSFORMED FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Joseph Tuscano • Aim: Disease control
Last updated May 17, 2026 05:36 UTC
-
Could a poop pill make cancer therapy work better?
Disease control Recruiting nowThis study tests whether a fecal transplant from healthy donors can repair gut damage caused by antibiotics and chemotherapy in lymphoma patients receiving CAR T-cell therapy. About 56 adults with relapsed or hard-to-treat lymphoma will be randomly assigned to get either the tran…
Matched conditions: RECURRENT TRANSFORMED FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Double punch: experimental drug may boost CAR-T success in tough lymphoma
Disease control Recruiting nowThis study tests whether adding the drug odronextamab before and after standard CAR-T cell therapy can help people with a type of aggressive lymphoma (DLBCL) that has returned or not responded to prior treatments. About 34 adults who have already tried at least two other therapie…
Matched conditions: RECURRENT TRANSFORMED FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Joseph Tuscano • Aim: Disease control
Last updated May 12, 2026 13:40 UTC